Valuation: Sorrento Therapeutics, Inc.

Market Cap 67.15M 58.74M 54.17M 50.12M 95.13M 6.41B 96.72M 649M 254M 3.15B 252M 247M 10.9B P/E 2021
-3.2x
P/E 2022 -0.65x
Enterprise Value 152M 133M 122M 113M 215M 14.48B 218M 1.47B 574M 7.11B 569M 557M 24.63B EV / Sales 2021
29.1x
EV / Sales 2022 7.89x
Free-Float
98.65%
Yield 2021 *
-
Yield 2022 -
1 day-15.38%
1 week+120.00%
Current month+83.33%
3 months-56.00%
6 months-60.71%
Current year-57.69%
1 week 0
Extreme 0.0004
0
1 month 0
Extreme 0.0004
0.01
Current year 0
Extreme 0
0.01
1 year 0
Extreme 0
0.1
3 years 0
Extreme 0
0.42
5 years 0
Extreme 0
9.63
10 years 0
Extreme 0
19.39
Manager TitleAgeSince
Chief Executive Officer 61 2011-03-31
Chief Tech/Sci/R&D Officer - 2022-02-28
General Counsel - -
Director TitleAgeSince
Chairman 61 2017-07-31
Date Insider Type Main position Quantity % Market Cap.
23-03-16Option

Chief Executive Officer

19,695 0.0042%
22-12-14Free

Chief Executive Officer

1,500,000 0.3179%
22-12-01Option

Chief Executive Officer

505 0.0001%
Change 5-day change 1-year change 3-year change Capi.($)
-15.38%+120.00%-21.43%-99.71% 598K
-0.38%-3.44%+71.35%+126.62% 56.71B
+4.91%-3.30%+71.97%+92.14% 51.3B
+1.72%+6.43%+23.13%+482.25% 25.26B
-0.87%-4.98%-17.08%-13.72% 23.65B
+3.93%+7.11%+44.20%-1.96% 18.69B
+2.01%+2.99%+40.72%-24.46% 17.71B
-6.84%+4.81%+201.88%+348.11% 17.7B
-0.92%+8.90%+38.48% - 14.26B
+1.54%+1.92%+29.16%+198.48% 14.1B
Average -1.03%+15.10%+48.24%+123.08% 23.94B
Weighted average by Cap. +1.04%+2.16%+58.48%+143.28%

Financials

2021 2022
Net sales 52.9M 46.28M 42.68M 39.49M 74.95M 5.05B 76.2M 511M 200M 2.48B 199M 194M 8.59B 62.84M 54.97M 50.69M 46.9M 89.03M 6B 90.51M 607M 238M 2.95B 236M 231M 10.2B
Net income -428M -375M -346M -320M -607M -40.88B -617M -4.14B -1.62B -20.08B -1.61B -1.57B -69.54B -573M -501M -462M -428M -812M -54.68B -825M -5.53B -2.17B -26.85B -2.15B -2.1B -93.01B
Net Debt 111M 96.84M 89.3M 82.62M 157M 10.57B 159M 1.07B 419M 5.19B 416M 407M 17.97B 84.53M 73.94M 68.19M 63.09M 120M 8.07B 122M 817M 320M 3.96B 317M 310M 13.72B
Logo Sorrento Therapeutics, Inc.
Sorrento Therapeutics, Inc. is a clinical and commercial stage biopharmaceutical company. The Company is engaged in developing a portfolio of next-generation treatments for cancer, infectious diseases and pain. It is also developing Resiniferatoxin (RTX), a naturally occurring non-opioid ultra-potent transient receptor potential vanilloid-1 agonist. The Company’s proprietary fully human G-MAB antibody library and ACEA small molecule library are the pipeline of new solutions for cancer. Its diagnostics platforms include the COVIMARK lateral flow antigen test and the VIREX platform.
Employees
949
Date Price Change Volume
26-07-08 US$0.001100 -15.38% 334,705
26-07-07 US$0.001300 +85.71% 27,846
26-07-06 US$0.000700 +27.27% 1,083,909
26-07-02 US$0.000550 +10.00% 36,109
26-07-01 US$0.000500 -16.67% 218,417
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
  1. Stock Market
  2. Stocks
  3. SRNE Stock